Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Kaku CI"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-3 z 3
    Tytuł:
    Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron.
    Autorzy:
    Liu H; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
    Kaku CI; Adimab, LLC, Lebanon, NH, USA.
    Song G; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
    Yuan M; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
    Andrabi R; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
    Burton DR; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
    Walker LM; Adimab, LLC, Lebanon, NH, USA. .; Adagio Therapeutics, Inc, Waltham, MA, USA. .
    Wilson IA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. .; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA. .
    Pokaż więcej
    Źródło:
    Communications biology [Commun Biol] 2022 Jul 29; Vol. 5 (1), pp. 766. Date of Electronic Publication: 2022 Jul 29.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    COVID-19*
    SARS-CoV-2*/genetics
    Antibodies, Viral ; Epitopes/genetics ; Humans ; Membrane Glycoproteins/metabolism ; Neutralization Tests ; Spike Glycoprotein, Coronavirus/genetics ; Viral Envelope Proteins/metabolism
    SCR Organism:
    SARS-CoV-2 variants
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.
    Autorzy:
    Kaku CI; Adimab, Lebanon, NH 03766, USA.; Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.
    Champney ER; Adimab, Lebanon, NH 03766, USA.
    Normark J; Division of Immunology, Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
    Garcia M; Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
    Johnson CE; Adimab, Lebanon, NH 03766, USA.
    Ahlm C; Division of Immunology, Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
    Christ W; Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
    Sakharkar M; Adimab, Lebanon, NH 03766, USA.
    Ackerman ME; Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.; Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.
    Klingström J; Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
    Forsell MNE; Division of Immunology, Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
    Walker LM; Adimab, Lebanon, NH 03766, USA.; Adagio Therapeutics, Waltham, MA 02451, USA.
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2022 Mar 04; Vol. 375 (6584), pp. 1041-1047. Date of Electronic Publication: 2022 Feb 10.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    2019-nCoV Vaccine mRNA-1273/*immunology
    Antibodies, Viral/*immunology
    COVID-19 Vaccines/*immunology
    ChAdOx1 nCoV-19/*immunology
    Memory B Cells/*immunology
    SARS-CoV-2/*immunology
    Spike Glycoprotein, Coronavirus/*immunology
    2019-nCoV Vaccine mRNA-1273/administration & dosage ; Adult ; Antibodies, Monoclonal/immunology ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Antibody Specificity ; ChAdOx1 nCoV-19/administration & dosage ; Female ; Humans ; Immunization Schedule ; Immunization, Secondary ; Immunogenicity, Vaccine ; Male ; Middle Aged ; Protein Conformation ; Protein Domains ; Spike Glycoprotein, Coronavirus/chemistry
    SCR Protocol:
    COVID-19 vaccine booster shot
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
    Autorzy:
    Rappazzo CG; Adimab, LLC, Lebanon, NH 03766, USA.
    Tse LV; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
    Kaku CI; Adimab, LLC, Lebanon, NH 03766, USA.
    Wrapp D; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
    Sakharkar M; Adimab, LLC, Lebanon, NH 03766, USA.
    Huang D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
    Deveau LM; Adimab, LLC, Lebanon, NH 03766, USA.
    Yockachonis TJ; Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA.
    Herbert AS; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.; The Geneva Foundation, Tacoma, WA 98402, USA.
    Battles MB; Adimab, LLC, Lebanon, NH 03766, USA.
    O'Brien CM; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.; The Geneva Foundation, Tacoma, WA 98402, USA.
    Brown ME; Adimab, LLC, Lebanon, NH 03766, USA.
    Geoghegan JC; Adimab, LLC, Lebanon, NH 03766, USA.
    Belk J; Adimab, LLC, Lebanon, NH 03766, USA.
    Peng L; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
    Yang L; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
    Hou Y; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
    Scobey TD; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
    Burton DR; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA.
    Nemazee D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
    Dye JM; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
    Voss JE; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
    Gunn BM; Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA.
    McLellan JS; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
    Baric RS; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. .; Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
    Gralinski LE; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. .
    Walker LM; Adimab, LLC, Lebanon, NH 03766, USA. .; Adagio Therapeutics, Inc., Waltham, MA 02451, USA.
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2021 Feb 19; Vol. 371 (6531), pp. 823-829. Date of Electronic Publication: 2021 Jan 25.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Antibodies, Monoclonal/*immunology
    Antibodies, Viral/*immunology
    Betacoronavirus/*immunology
    Broadly Neutralizing Antibodies/*immunology
    SARS-CoV-2/*immunology
    Spike Glycoprotein, Coronavirus/*immunology
    Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Antibodies, Monoclonal/genetics ; Antibodies, Monoclonal/metabolism ; Antibodies, Viral/genetics ; Antibodies, Viral/metabolism ; Antibody Affinity ; Binding Sites ; Binding Sites, Antibody ; Broadly Neutralizing Antibodies/genetics ; Broadly Neutralizing Antibodies/metabolism ; COVID-19/prevention & control ; COVID-19/therapy ; Cell Surface Display Techniques ; Directed Molecular Evolution ; Epitopes/immunology ; Humans ; Immunization, Passive ; Immunoglobulin Fc Fragments/immunology ; Mice, Inbred BALB C ; Protein Domains ; Protein Engineering ; Receptors, Coronavirus/metabolism ; Severe acute respiratory syndrome-related coronavirus/immunology ; Severe Acute Respiratory Syndrome/immunology ; Severe Acute Respiratory Syndrome/prevention & control ; Severe Acute Respiratory Syndrome/therapy ; Spike Glycoprotein, Coronavirus/metabolism ; COVID-19 Serotherapy ; Mice
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-3 z 3

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies